Stop and Seek Help If Severe allergic reaction (rash, swelling, difficulty breathing) Persistent severe nausea or vomiting not improving with dose reduction Signs of pancreatitis (severe abdominal pain radiating to back) Planned pregnancy or positive pregnancy test Inability to maintain adequate nutrition despite dose adjustments Any concerning symptoms your healthcare provider advises stopping for Always consult your healthcare provider before stopping or modifying your dose
For temperature, light, and freeze-thaw guidance, see Storage and Stability of Cagrilintide Research Peptide
GHK-Cu Dosage Information From Studies and Protocols GHK-Cu dosage information should be interpreted as study context, not personal dosing advice
It is not a drug, food, supplement, or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease, or for human or veterinary consumption
Sermorelin is added as a nightly subcutaneous injection
One of the most studied combinations pairs Cagrilintide with Semaglutide together referred to as CagriSema to investigate complementary appetite and metabolic pathways